Bangladesh vs Belgium: Pneumococcal conjugate second or third-dose vaccines (PCVc)
Bangladesh
94.0%
in 2025
Belgium
94.0%
in 2025
Bangladesh rank
46th
Belgium rank
46th
Pneumococcal conjugate second or third-dose vaccines (PCVc) over time
- Bangladesh
- Belgium
How they compare
Bangladesh currently reports 94.0% against 94.0% in Belgium, a difference of 0.0%.
The two have swapped places 2 times across 18 shared years of data; in 2008 it was Belgium ahead.
Bangladesh ranks 46th and Belgium ranks 46th of 194 countries.
Across the 3 decades both report, Bangladesh averaged higher in 1 and Belgium in 1.
Head to head by decade
| Decade | Bangladesh | Belgium | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 0.0% | 0.0% | 0.0% | — |
| 2010s | 44.1% | 74.9% | 30.8% | Belgium |
| 2020s | 96.8% | 94.0% | 2.8% | Bangladesh |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher pneumococcal conjugate second or third-dose vaccines (pcvc), Bangladesh or Belgium?
- Bangladesh, at 94.0% against 94.0% in Belgium as of 2025.
- What is the difference in pneumococcal conjugate second or third-dose vaccines (pcvc) between Bangladesh and Belgium?
- 0.0%, with Bangladesh ahead.
- How many years of comparable data are there for Bangladesh and Belgium?
- 18 years are reported by both, from 2008 to 2025.
- How do Bangladesh and Belgium rank globally for pneumococcal conjugate second or third-dose vaccines (pcvc)?
- Bangladesh ranks 46th and Belgium ranks 46th of 194 countries.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as Pneumococcal conjugate second or third-dose vaccines (PCVc) immunization coverage by the locally recommended age (%) (WUENIC). Statizoid refreshes it automatically from the source and publishes the full history for both places.